Initiator Pharma A/S
Research Initiator Pharma A/S (INIT) on Bullrun: market cap SEK 134.85M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerINIT
- ExchangeST
- CountryDenmark
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 134.85M
- Financial periodQ1 2026
- RevenueDKK 0
- Net income-DKK 11.55M
- Free cash flow-DKK 11.81M
Valuation Snapshot
latest market cap is SEK 134.85M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | DKK 0 | -DKK 13.69M | -DKK 17.72M | n/a | -0.22 | DKK 26.25M | DKK 2.15M | DKK 29.55M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-05 | SEK 134.85M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Initiator Pharma A/S
Initiator Pharma A/S, a clinical-stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous systems. The company is developing Pudafensine, a monoamine reuptake inhibitor that has completed a Phase IIb clinical trial primarily targeting the dopamine system for the treatment of treatment-resistant organic erectile dysfunction; a Phase IIa trial for the treatment of vulvodynia; and preclinical development for the treatment of female sexual dysfunction (FSD).
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Initiator Pharma A/S's market cap?
Initiator Pharma A/S's market capitalization is SEK 134.85M.
What does Initiator Pharma A/S do?
Initiator Pharma A/S, a clinical-stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous systems. The company is developing Pudafensine, a monoamine reuptake inhibitor that has completed a Phase IIb clinical trial primarily targeting the dopamine system for the treatment of treatment-resistant organic erectile dysfunction; a Phase IIa trial for the treatment of vulvodynia; and preclinical development for the treatment of female sexual dysfunction (FSD).